Immunotherapy and Innovative Breast Cancer Treatments in the UK
Immunotherapy is an emerging treatment approach that helps the body’s immune system identify and attack cancer cells. In the UK, immunotherapy is currently used for selected types of breast cancer, particularly certain forms of triple-negative breast cancer.
Cancer cells can evade immune detection by suppressing immune responses. Immunotherapy drugs work by blocking these suppression signals, allowing immune cells to recognise and destroy cancer more effectively. These treatments are often given intravenously in specialist oncology units.
Immunotherapy may be used alone or in combination with chemotherapy, depending on the cancer’s characteristics. Genetic and molecular testing helps determine which patients are most likely to benefit from this approach.
Side effects of immunotherapy are different from traditional cancer treatments. Because the immune system is activated, inflammation-related effects may occur, affecting the skin, lungs, digestive system, or hormone-producing glands. Early recognition and management of these effects are essential.
UK oncology teams closely monitor patients receiving immunotherapy, providing education on symptom reporting and offering prompt treatment for immune-related reactions.
Innovative therapies, including antibody-drug conjugates and personalised treatment strategies, are also expanding breast cancer care options. These advances reflect a shift toward more precise and effective treatments.
Immunotherapy and innovation continue to shape the future of breast cancer care, offering new hope for selected patients within the UK healthcare system.